



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known	
			Application Number	09/992.095
			Filing Date	November 13, 2001
			First Named Inventor	BEJANIN, et al.
			Art Unit	1645
			Examiner Name	Unassigned
			Attorney Docket Number	91.US5.DIV
Sheet	1	of	4	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. 1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
85	A	US- 5,753,486	05-19-1998	Goeddel, et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			


FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. 1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
85	B	WO 94/03614 - A1	02-17-1994	British Bio-Technology Lt		

Examiner Signature	<i>Snape</i>	Date Considered	10/23/04
--------------------	--------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	09/992.095	
Sheet	2	of	4	Filing Date	November 13, 2001
			First Named Inventor	BEJANIN, et al.	
			Group Art Unit	1645	
			Examiner Name	Unassigned	
			Attorney Docket Number	91.US5.DIV	


OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
[Handwritten marks]	C	DANIS, R., et al.; "Anti-angiogenic therapy of proliferative diabetic retinopathy"; Exp.Opin.Pharmacother. (2001) 2(3):395-407; Ashley Publications Ltd. ISSN 1465-6566	
	D	CASTELLINO, Francis; "Plasminogen"; pgs. 495-515; Molecular Basis of Thrombosis and Hemostasis, edited by Katherine A. High & Harold R. Roberts; Marcel Dekker, Inc., New York, NY; ISBN 0-8247-9501-6 (1995)	edited by
	E	ELLENRIEDER, V., et al.; "Invasion and metastasis in pancreatic cancer"; Annals of Oncology, 10, suppl. 4, 41-45, 1999; Kluwer Academic Publishers, Netherlands	
	F	MOROZ, L., et al.; "Mini-Plasminogen-like Fragments of Plasminogen in Synovial Fluid in Acute Inflammatory Arthritis"; Thrombosis Research 43: 417-424, 1986; 0049-3848/86; Pergamon Journals Ltd.	
	G	CARMELET, P., et al.; "Impaired Arterial Neointima Formation in Mice with Disruption of the Plasminogen Gene"; J. Clin. Invest.; Vol. 99, No. 2, January 1997, 200-208; The American Society for Clinical Investigation, Inc.; 0021-9738/97/01/200/09	
	H	SWIERCZ, R., et al.; "Recombinant PAI-1 inhibits angiogenesis and reduces size of LNCaP prostate cancer xenografts in SCID mice"; Oncology Reports 8: 463-470, 2001	
	I	CASTELLINO, F., et al.; "The kringle domains of human plasminogen"; Ciba Found Symp 212:46-60 (1997)	
	J	MOROZ, L., et al.; "Mini-Plasminogen: A Mechanism for Leukocyte Modulation of Plasminogen Activation by Urokinase"; Blood, Vol. 58, No. 1 (July) 1981; Grune & Stratton, Inc.; 0006-4971/81/5801-0014	pgs 97-104
	K	BEWLEY, Thomas; "Optical Activity of Disulfide Bonds in Proteins. 1. Studies on Plasmin Modified Human Somatotropin"; Biochemistry, Vol. 16, No. 2, 1977, pp 209-215	
	L	KOST, C., et al.; "Limited plasminolysis of vitronectin - Characterization of the adhesion proteins as morpho-regulatory and angiostatin-binding factor"; Eur. J. Biochem, 236, 682-688 (1996); FEBS 1996	
M	MORII, T., et al.; "Prognostic Relevance of Urokinase Type Plasminogen Activator, Its Receptor and Inhibitors in Chondrosarcoma"; Anticancer Research 20: 3031-3036 (2000); 0250-705/2000		

Examiner Signature	[Handwritten Signature]	Date Considered	10/23/04
--------------------	-------------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line-through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

PTO/SB/088 (10-01)

Substitute for form 1449B/PTO		Complete if Known	
		Application Number	09/992.095
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	November 13.2001
		First Named Inventor	BEJANIN. et al.
		Group Art Unit	1645
		Examiner Name	Unassigned
		Attorney Docket Number	91.US5.DIV
Sheet	3	of	4

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
85	N	KONNO, H., et al.; "Urokinase Receptor and Vascular Endothelial Growth Factor are Synergistically Associated with Liver Metastasis of Colorectal Cancer"; Jpn. J.Cancer Res.; 92, 516-523, May 2001	
	O	ROMER, J., et al.; "Cancer Cell Expression of Urokinase-Type Plasminogen Activator Receptor mRNA in Squamous Cell Carcinomas of the Skin"; The Journal of Investigative Dermatology; Vol. 116, No. 3, March 2001, pgs. 353-358; The Society for Investigative Dermatology, Inc.; 0022-202X/01	
	P	ITOH, Y., et al.; "Highly Increased Plasma Concentrations of the Nicked Form of B2Glycoprotein I in Patients with Leukemia and with Lupus Anticoagulant: Measurement with a Monoclonal Antibody Specific for a Nicked Form of Domain V"; J.Biochem, Vol. 128, No. 6, pgs. 1017-1024 (2000)	
	Q	ANDREASEN, et al.; "The plasminogen activation system in tumor growth, invasion, and metastasis"; CMLS Cellular and Molecular Life Sciences, 57 (2000) 25-40; 1420-682X/00/010025-16; Birkhauser Verlag, Basel	
	R	SHI, G.Y., et al.; "Isolation and Characterization of Microplasminogen"; The Journal of Biological Chemistry, Vol. 263, No. 32, Issue of November 15, pp. 17071-17075, 1988; The American Society for Biochemistry and Molecular Biology, Inc.	
	S	CREEMERS, et al.; "Disruption of the Plasminogen Gene in Mice Abolishes Wound Healing after Myocardial Infarction"; American Journal of Pathology, Vol.156, No.6, June 2000; American Society for Investigative Pathology Ap 1865-1873	85 id 23/04
	T	PETERSEN, T., et al.; "Characterization of the Gene for Human Plasminogen, a key Proenzyme in the Fibrinolytic System"; The Journal of Biological Chemistry, Vol. 265, No. 11, Issue of April 15, pp. 6104-6111, 1990; The American Society for Biochemistry and Molecular Biology, Inc.	
	U	HE, C., et al.; "Analysis of expressions of components in the plasminogen activator system in high- and low-metastatic human lung cancer cells"; J. Cancer Res Clin Oncol (2001) 127:180-186; Springer-Verlag 2000	
	V	BORGELDT, C.; "Dedifferentiation of Serous Ovarian Cancer from Cystic to Solid Tumors is Associated with Increased Expression of mRNA for Urokinase Plasminogen Activator (uPA), its Receptor (uPAR) and its Inhibitor (PAI-1); Int. J. Cancer; 92, 497-502 (2001); Wiley-Liss, Inc.; Publication of the International Union Against Cancer	
	W	TECIMER, C., et al.; "Clinical Relevance of Urokinase-Type Plasminogen Activator, Its Receptor, and its Inhibitor Type 1 in Endometrial Cancer"; Gynecologic Oncology 80, 48-55 (2001); 0090-8258/01; Academic Press	
	X	ZHENG, Q., et al.; "Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor"; J Cancer Res Clin Oncol (2000) 126:641-646; Springer-Verlag 2000	

Examiner Signature	<i>Snipe</i>	Date Considered	10/23/04
--------------------	--------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/088 (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Project of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/992.095
		Filing Date	November 13, 2001
		First Named Inventor	BEJANIN, et al.
		Group Art Unit	1645
		Examiner Name	Unassigned
Sheet 4 of 4	Attorney Docket Number	91.US5.DIV	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
KS	Y	ABE, J., et al.; "Larger and More Invasive Colorectal Carcinoma Contains Larger Amounts of Plasminogen Activator Inhibitor Type 1 and Its Relative Ratio over Urokinase Receptor Correlates Well with Tumor Size"; Cancer, December 15, 1999; Vol. 86, No. 12, pp. 2602-2611; 199 American Cancer Society	
	Z	FISHER, J., et al.; "The Expression of the Urokinase Plasminogen Activator System in Metastatic Murine Osteosarcoma: An in Vivo Mouse Model"; Clinical Cancer Research; Vol. 7, 1654-1660, June 2001	
	aa	ROMER, J., et al.; "Impaired wound healing in mice with a disrupted plasminogen gene"; Nature Medicine, Vol. 2, No. 3, March 1996, pp.287-292	
	ab	Accession No: AAR34428; Foster, et al.; "Human tissue plasminogen activator single chain form fibrinolytic agent - comprises thrombin cleavable zymogen stimulating amido lytic activity, for lysing clots in heart attack and stroke victims and suppressing fibrin matrix"	
	ac	Accession No. AAR56472; Dawson, et al.; "New modified serine protease(s) resistant to inhibitors - having a mutation at a residue in close spatial proximity to a site of interaction between the protease and inhibitor"	
	ad	Accession No. CAA02277; Dawson, et al.; "Inhibitor resistant serine proteases" NCBI Data Base	
	ae	Accession No. P00747; Petersen, et al.; "Characterization of the gene for human plasminogen, a key proenzyme in the fibrinolytic system" NCBI Data Base	
af	Accession No. AL109933; Tracey, A.; "Human DNA sequence from clone RP1-81D8 on chromosome 6q25.3-26" NCBI Data Base		

Examiner Signature	<i>Swope</i>	Date Considered	10/23/04
--------------------	--------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.